Compare TANH & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TANH | INDP |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.7M |
| IPO Year | 2015 | N/A |
| Metric | TANH | INDP |
|---|---|---|
| Price | $0.83 | $1.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 216.0K | 95.0K |
| Earning Date | 05-15-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.88 | N/A |
| Revenue | ★ $41,982,988.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $1.65 |
| 52 Week High | $5.86 | $47.60 |
| Indicator | TANH | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 31.67 | 30.84 |
| Support Level | $0.73 | $2.60 |
| Resistance Level | $1.06 | $2.66 |
| Average True Range (ATR) | 0.09 | 0.28 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 22.20 | 1.90 |
Tantech Holdings Ltd manufactures bamboo charcoal-based products. The company, through its subsidiaries, is engaged in the production and distribution of household products along with a trading business, which involves the export of charcoal products. It also manufactures electric double-layer capacitors carbon materials and low-emission barbecue charcoal. Its product portfolio includes air purifiers and humidifiers, underfloor humidity control, pillows and mattresses, wardrobe deodorizers, mousepads, and wrist mats, refrigerator deodorant, and charcoal toilet cleaner disks. The company has two reportable segments: the Consumer Product segment, and the Electric Vehicle (EV) segment.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.